Full-Time

Quality Assurance Auditor 1

Inotiv

Inotiv

1,001-5,000 employees

Global CRO for life sciences research

No salary listed

Research Triangle Park, Durham, NC, USA

In Person

Occasional business travel may be required, including transit between buildings or sites.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
SharePoint
Word/Pages/Docs
Quality Assurance (QA)
Excel/Numbers/Sheets
Microsoft Outlook

Get referred to Inotiv

See people who can refer or advise you

Requirements
  • A B.S. in chemistry or life sciences, or a bachelor's degree or higher in a related field.
  • Two to four years of experience in a good laboratory practice or similarly regulated environment, preferably including one or more years of auditing experience, or an equivalent combination of education and regulatory, quality, compliance, and/or industry experience.
  • Excellent written and verbal communication and interpersonal skills with the ability to work with personnel at all levels of the organization.
  • Good organizational skills and attention to detail.
  • Working knowledge and awareness of general laboratory procedures.
  • Ability to comprehend and apply applicable government regulations.
  • Versatility and accuracy when performing various tasks, including difficult and non-routine tasks.
  • Ability to work independently and follow written instructions.
  • Proficiency with computer software applications needed to conduct quality assurance duties, including Word, Outlook, Excel, and SharePoint.
  • Analytical thinking ability to understand problems, determine root causes, and recommend appropriate solutions.
  • Ability to read, write, speak, and understand oral and written instructions.
  • Availability for occasional business travel.
  • Ability to stand and/or walk for four or more hours per day, perform repetitive hand and finger movements, reach, lift up to 50 pounds, and sit for prolonged periods while working at a computer.
  • Ability to transit between buildings or sites and walk over rough terrain when required.
  • Ability to work in office or laboratory environments with possible exposure to dust, fumes, animal dander, moderate noise, hazardous chemicals, and biohazards.
  • Ability to use required personal protective equipment, including latex or nitrile gloves, dust masks or respirators, and safety glasses.
  • Negative Mantoux tuberculosis test or chest X-ray may be required at some sites.
Responsibilities
  • Demonstrate Inotiv core values.
  • Follow all standard operating procedures and other applicable laboratory or company policies and procedures.
  • Maintain confidential information.
  • Interact with clients, employees, and the community in a professional manner.
  • Support and participate in company initiatives as directed.
  • Maintain thorough knowledge of facility standard operating procedures, policies, study protocols, and related materials.
  • Adhere to all safety regulations and procedures.
  • Provide assistance or support to other Inotiv quality assurance team members as necessary.
  • Demonstrate a solid understanding of the application and interpretation of FDA and EPA good laboratory practices and applicable international regulations.
  • Keep abreast of new rules, guidance, and industry standards to improve laboratory compliance.
  • Conduct audits of designated studies and facilities to assess compliance with protocols, standard operating procedures, methods, and relevant regulations, including direct observation, document review, data and report review, facility-record and standard-operating-procedure review, and subcontractor-contribution review.
  • Conduct audits of validations, including risk assessments, user requirements, and validation summary reports against Part 11 compliance.
  • Prepare audit reports and promptly submit findings to the Study Director, Principal Investigator, and management.
  • Issue accurate quality assurance statements for inclusion in final reports.
  • Become familiar with electronic data collection systems used in data generation, including proper use, reporting, audit trails, security, Part 11 compliance, data correction, and quality control.
  • Input and update information in the Master Schedule program as required by good laboratory practice regulations and standard operating procedures.
  • Independently conduct process or facility inspections.
  • Assist with audits and inspections conducted by sponsors and regulatory agencies as requested.
  • Conduct quality training for new hires and other employees as assigned.
  • Participate in or lead subcontractor and vendor evaluations.
  • Represent the quality assurance team as a resource on regulatory topics, including at study initiation meetings, as requested.
  • Participate in departmental business, process, and general regulatory projects as assigned.
  • Perform other duties as assigned.
Desired Qualifications
  • Experience with quality systems management and enterprise quality management software.

Inotiv provides contract research services across drug discovery, preclinical testing, analytical testing, and related areas for the pharmaceutical and biotech industries. Its offerings combine analytical chemistry, preclinical research, and access to a broad set of research models to generate data and prepare regulatory-compliant documentation that supports drug development, safety testing, and medical device evaluation. The company differentiates itself through an integrated CRO model that pairs BASi’s analytical capabilities, Seventh Wave’s preclinical work, and Envigo’s research models in one end-to-end service. Its goal is to be a global partner for drug discovery, safety assessment, and product development by delivering scalable research services and regulatory-grade data to biopharma and medical device customers.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

West Lafayette, Indiana

Founded

1974

Get referred to Inotiv

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 20, 2026 restructuring improved liquidity and strengthened Inotiv's balance sheet.
  • Q1 fiscal 2026 backlog reached $145.4 million, supporting near-term DSA revenue visibility.
  • Management kept normal operations through bankruptcy, preserving clients, vendors, and service continuity.

What critics are saying

  • June 2026 Chapter 11 cancelled existing equity, wiping out prior shareholders.
  • USDA cited Inotiv facilities in April 2026 and August 2026 for critical violations.
  • Animal-welfare scandals and bankruptcy stigma threaten customer trust and future contract wins.

What makes Inotiv unique

  • Inotiv pairs preclinical CRO services with research models and analytical capabilities.
  • July 2026 emergence from Chapter 11 cut about $326 million of debt.
  • Its VUGENE collaboration adds AI bioinformatics across Discovery and Translational Sciences.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Pension

Life Insurance

Wellbeing Program

Paid Time Off

401(k) Retirement Plan

Flexible Work Hours

Remote Work Options

Stock Options

Company Equity

Conference Attendance Budget

Professional Development Budget

Family Planning Benefits

Fertility Treatment Support

Parental Leave

Paid Holidays

Short-term Disability

Long-term Disability

Dental Insurance

Vision Insurance

Phone/Internet Stipend

Home Office Stipend

Paid Vacation

Paid Sick Leave

Flexible Benefits Scheme

Employee Assistance Program

Private Health Insurance

Health cash plan

Retail discounts

Education allowance

Tuition Reimbursement

Meal Benefits

Adoption Assistance

Growth & Insights and Company News

Headcount

6 month growth

19%

1 year growth

19%

2 year growth

19%
Pryor Cashman
Jun 22nd, 2026
Pryor Cashman represents Acquiom Agency Services as DIP Agent and administrative and collateral in Inotiv Chapter 11 cases.

Pryor Cashman represents Acquiom Agency Services as DIP Agent and administrative and collateral in Inotiv Chapter 11 cases. Pryor Cashman has been engaged as counsel to Acquiom Agency Services LLC ("Acquiom"), in its roles as (i) DIP Agent for the Debtor-in-Possession Loan Credit Agreement, and (ii) administrative and collateral agent under the Prepetition First Lien Credit Agreement in the Chapter 11 bankruptcy cases of Inotiv, Inc. ("Inotiv") and its affiliated debtors. Inotiv is a contract research organization that provides drug discovery and development services to the pharmaceutical and medical device industries. On June 3, 2026, Inotiv and certain of its affiliates filed for bankruptcy protection in the United States Bankruptcy Court for the Southern District of Texas. The Pryor Cashman team representing Acquiom includes Partner Seth H. Lieberman, Chair of the Bankruptcy, Reorganization, and Creditors' Rights Group and Co-Chair of the Corporate Trust Practice; Partner Patrick Sibley, Co-Chair of the Corporate Trust Practice; Partner David W. Smith; Counsels Arsala Kidwai and Andrew S. Richmond; and Associate Daniel Brenner.seth Related people. Related services & industries. Firm Highlights Slide 1 of 10

Inotiv
Jun 3rd, 2026
Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth

Receives commitments for $65 million in new money financing to support ongoing business operations Recapitalization effectuated through a pre-packaged plan of reorganization on an expedited basis Transaction is supported by substantially all of the Company’s existing lenders Normal business operations will continue seamlessly with no impact on vendors and suppliers Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it has entered into a Restructuring Support Agreement (“RSA”) with its Prepetition First Lien Lenders and Ad Hoc Group of Noteholders, constituting substantially all of its junior creditors, to implement a comprehensive recapitalization transaction that will strengthen its capital structure. To implement the transaction, Inotiv has filed a voluntary, prepackaged chapter

StockTitan
Dec 11th, 2025
Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities

Inotiv partners with VUGENE to advance ai-driven drug Discovery and bioinformatics capabilities. Rhea-AI summary. Inotiv (NASDAQ: NOTV) announced a strategic collaboration with VUGENE on December 11, 2025 to integrate VUGENE's cloud-based AI/ML multi-omics bioinformatics platform into Inotiv's Discovery & Translational Sciences Division. The partnership aims to accelerate AI-assisted drug discovery by improving interpretation of epigenomic, proteomic, and other molecular datasets to better predict drug efficacy and safety in early-stage research. Inotiv said the integration will enable more efficient, data-driven decision making for client discovery programs, while VUGENE expects broader application of its computational technologies in real-world research settings. News market reaction 1 alert. On the day this news was published, NOTV declined 4.48%, reflecting a moderate negative market reaction. Data tracked by StockTitan Argus on the day of publication. Technical Shares at 0.8414 are trading below the 200-day MA of 1.87 and 87.02% under the 52-week high. Peers on Argus 1 down. Sector peers show mixed moves, with ADVB down 9.61% and others modestly up or down. With only one peer in momentum and no shared news, the AI-focused partnership appears company-specific rather than part of a sector-wide move. Historical context. | Date | Event | Sentiment | Move | Catalyst | | Dec 03 | Earnings report | Positive | +8.1% | Reported FY2025 revenue growth and sharply reduced operating loss. | | Nov 25 | Growth ranking | Positive | +3.9% | Ranked 182nd on Deloitte Technology Fast 500 with 448% growth. | | Nov 21 | Earnings date notice | Neutral | -3.9% | Announced timing and access details for FY2025 results call. | | Nov 17 | Preliminary results | Positive | -33.2% | Shared preliminary FY2025 revenue and strong DSA growth metrics. | | Oct 21 | Conference participation | Neutral | -2.2% | Outlined participation in multiple November investor conferences. | Operationally positive news has sometimes aligned with gains but also seen sharp selloffs, indicating inconsistent market confidence in updates. Over the last few months, Inotiv reported improving FY2025 results with Q4 revenue of $138.1M and FY revenue of $513.0M, alongside a narrowed operating loss of $30.9M. Recognition on the 2025 Deloitte Technology Fast 500(TM) and strong DSA growth, with backlog around $138M, highlight expansion. However, preliminary results on Nov 17, 2025 coincided with a -33.2% move, contrasting with the later earnings-day gain of 8.13%. Today's AI partnership adds to a pattern of strategic initiatives amid volatile reactions. Regulatory & risk context. An effective S-3 shelf filed on 2025-08-29 allows future securities offerings, including an at-the-market equity program with up to 3.0% commission. The filing highlights an auditor's explanatory paragraph raising substantial doubt about going-concern status, material weaknesses in internal control, and warns of immediate dilution risk and variable ATM proceeds. Market pulse summary. This announcement details a strategic collaboration integrating VUGENE's AI-enabled bioinformatics platform into Inotiv's Discovery & Translational Sciences Division to better analyze complex epigenomic and proteomic data. It follows FY2025 revenue of $513.0M and recognition in the 2025 Deloitte Technology Fast 500(TM). Regulatory filings, including the 2025-08-29 S-3, highlight going-concern language, internal-control weaknesses, and dilution risk. Investors may watch how this AI partnership translates into Discovery and Safety Assessment growth and backlog trends.

StockTitan
Dec 23rd, 2024
Inotiv Raises $24M in Equity Offering

Inotiv completed an equity offering, raising approximately $24 million by selling 6 million common shares at $4.25 each. The offering closed on December 19, 2024, with Lake Street Capital Markets as the sole book-running manager. An option allows underwriters to purchase up to 900,000 additional shares until January 17, 2025. The funds will be used for working capital, capital expenditures, and general corporate purposes to enhance financial flexibility and support strategic initiatives.

GlobeNewswire
Dec 18th, 2024
Inotiv, Inc. Announces Pricing of Public Offering of 6,000,000 Common Shares

WEST LAFAYETTE, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization...